MetLife Investment Management’s Alder Biopharmaceuticals ALDR Stock Holding History

MetLife Investment Management’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-34,309	Closed	-$647K	–	2380
2019 Q3	$647K	Hold	34,309	–	–	0.01%	1285
2019 Q2	$404K	Buy	34,309 +9,263	+37%	+$112K	﹤0.01%	1608
2019 Q1	$342K	Hold	25,046	–	–	﹤0.01%	1678
2018 Q4	$257K	Hold	25,046	–	–	﹤0.01%	1773
2018 Q3	$417K	Sell	25,046 -5,635	-18%	-$102K	﹤0.01%	1644
2018 Q2	$485K	Hold	30,681	–	–	0.01%	1418
2018 Q1	$390K	Hold	30,681	–	–	﹤0.01%	1525
2017 Q4	$351K	Buy	+30,681	New	+$342K	﹤0.01%	1617

MetLife Investment Management's ALDR Position: Q4 2019 in Review

MetLife Investment Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 34,309 shares — an estimated $647K sold.

MetLife Investment Management first reported a position in ALDR in Q4 2017 and held it in 8 quarters. The position peaked at $647K in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

MetLife Investment Management reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
MetLife Investment Management sold 34,309 Alder Biopharmaceuticals shares in Q4 2019, an estimated $647K.
MetLife Investment Management first reported a position in Alder Biopharmaceuticals in Q4 2017 and held it in 8 quarters.
MetLife Investment Management's Alder Biopharmaceuticals position peaked at $647K in Q3 2019.
0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on MetLife Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.